Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 11, 2021

LoA Update: Merus’ zenocutuzumab has a five-point increase in chances for transition to next development stage in solid tumours after Phase I/II data at ASCO

Merus’ Phase I/II zenocutuzumab asset to treat tumours harbouring NRG1 fusions saw its Phase Transition Success Rate (PTSR) jump five points to 28%.

By William Newton

Merus’ Phase I/II zenocutuzumab asset to treat tumours harbouring NRG1 fusions saw its Phase Transition Success Rate (PTSR) jump five points to 28%. The update occurred on 7 June on the heels of a pooled data analysis from an ongoing trial being presented at the 2021 ASCO Annual Meeting. The virtual conference took place 4–8 June.

PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. In the 250-patient Phase I/II eNRGy study among 45 patients, 34 reported tumour reduction and the overall response rate (ORR) was 29% (abstract no:TPS3145). The estimated primary completion date for the study is in September 2021, according to ClinicalTrials.gov. Zenocutuzumab acts by binding to Her2 and blocking Her3 interaction with NRG1 or NRG1-fusion proteins, thus potentially being effective against NRG1+ cancers.

The data update also resulted in a modest one-point increase in the drug’s Likelihood of Approval (LoA) taking it to 8%. LoA is identified via GlobalData’s analysis using a combination of machine learning and a proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Merus has a market cap of $888.6m.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU